PPAR-γ agonist rosiglitazone ameliorates peritoneal deterioration in peritoneal dialysis rats with LPS-induced peritonitis through up-regulation of AQP-1 and ZO-1

Peritonitis is still a major cause of the death in peritoneal dialysis (PD) patients despite the significant decline of the peritonitis rates in recent years. The present study is designed to evaluate the therapeutic potential of peroxisome proliferator-activated receptor-γ agonist, rosiglitazone, o...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yunfang, Feng, Junxia, Wang, Qi, Zhao, Shili, Xu, Jiaqi, Li, Hongyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Portland Press Ltd. 2018
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6013694/
https://www.ncbi.nlm.nih.gov/pubmed/29871973
http://dx.doi.org/10.1042/BSR20180009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6013694/
https://www.ncbi.nlm.nih.gov/pubmed/29871973
http://dx.doi.org/10.1042/BSR20180009

Ejemplares similares